To define critical parameters concerning interferon (IFN) effects upon natural killer (NK) cells in vivo, we gave cancer patients serial weekly intramuscular injections of purified lymphoblastoid IFN in six doses ranging from 10(5) to 3 X 10(7) U. Dose sequences were determined by randomly allocating patients to one of six levels in a latin square ordering scheme. NK cell stimulation, a threefold peak increase above preinjection levels of cytolysis (P = 0.022), occurred in peripheral mononuclear cells (PMC) sampled 24 h postinjection, of 3 X 10(6) U, but was not detectable at any dose in PMC sampled 7 d postinjection. No blunting occurred in NK cell responsiveness to repeated injection of IFN dosages a second time at or several weeks after study completion. At IFN doses of 3 X 10(6), 10(7), and 3 X 10(7) U, a negative correlation existed between the amount of IFN injected and the average extent of NK cell activation (r = -0.423, P less than 0.05). This contrasted with the progressively increasing response of NK cells to in vitro incubation with increasing concentration of up to 3,000 U/ml of IFN. Overnight culturing of PMC sampled before IFN injections resulted in a mean 1.9-fold increase in cytolytic activity (P = 0.0005) and a mean 53% decrease in variance (P = 0.024) between serial preinjection NK cell activity determinations. Cell separation procedures may, therefore, have resulted in NK cell inactivation, from which overnight culturing permitted recovery. We found that maximal NK cell activation at a low IFN dose, decreasing NK cell responsiveness at higher doses, and the need to culture PMC to efficiently detect NK cell boosting may account for disparities in reported effects of IFN on NK cell function.
B S Edwards, J A Merritt, R C Fuhlbrigge, E C Borden
Title and authors | Publication | Year |
---|---|---|
Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy
Zhang Y, Hong W, Zheng D, Li Z, Hu Y, Chen Y, Yang P, Zeng Z, Du S |
Clinical and Experimental Immunology | 2024 |
Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma
Xiao L, Huang Y, Li Q, Wang S, Ma L, Fan Z, Tang Z, Yuan X, Liu B |
Frontiers in Molecular Biosciences | 2022 |
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien, Catalina Rozalen, Toni Celià-Terrassa |
Journal of Clinical Investigation | 2021 |
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
DJ Zanker, KL Owen, N Baschuk, AJ Spurling, BS Parker |
Cancer Immunology, Immunotherapy | 2021 |
Cancer Immunology: Bench to Bedside Immunotherapy of Cancers
N Rezaei |
2020 | |
Interferons α and β in cancer: therapeutic opportunities from new insights
EC Borden |
Nature Reviews Drug Discovery | 2019 |
Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis
KL Owen, BS Parker |
Molecular Immunology | 2017 |
Interferon related pericarditis: Review
K Nishio, T Arase, H Tada, H Tachibana |
World journal of cardiology | 2017 |
Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
F Ashraf, F Marmoush, MI Shafi, A Shah |
Case Reports in Cardiology | 2016 |
Interferons and Their Stimulated Genes in the Tumor Microenvironment
HJ Cheon, EC Borden, GR Stark |
Seminars in Oncology | 2014 |
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
H Kaufman, M Wong, G Daniels, D McDermott, S Aung, J Lowder, M Morse |
Journal of Personalized Medicine | 2014 |
Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet's Uveitis Refractory to Conventional Treatments
G Sobacı, Ü Erdem, AH Durukan, C Erdurman, A Bayer, S Köksal, S Karagul, MZ Bayraktar |
Ophthalmology | 2010 |
Principles of Cancer Biotherapy
RK Oldham, RO Dillman |
2009 | |
Intratumoral Dendritic Cells and Chemoradiation for the Treatment of Murine Squamous Cell Carcinoma
JS Moyer, J Li, S Wei, S Teitz-Tennenbaum, AE Chang |
Journal of Immunotherapy | 2008 |
Regulation of Activated CD4+ T Cells by NK Cells via the Qa-1–NKG2A Inhibitory Pathway
L Lu, K Ikizawa, D Hu, MB Werneck, KW Wucherpfennig, H Cantor |
Immunity | 2007 |
Positive and negative regulation of Natural Killer cells: Therapeutic implications
WH Hallett, WJ Murphy |
Seminars in Cancer Biology | 2006 |
Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine
CJ Harrison, RL Miller, DI Bernstein |
Vaccine | 2001 |
Head and Neck Cancer
A Forastiere, W Koch, A Trotti, D Sidransky |
New England Journal of Medicine | 2001 |
RETRACTED: Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial
H Demiroglu, OI Özcebe, I Barista, S Dündar, B Eldem |
The Lancet | 2000 |
Mild hyperthermia modulates biological activities of interferons
J Payne, MP Nair, JL Ambrus, KC Chadha |
International Journal of Hyperthermia | 2000 |
Autoimmunity induced by interferon-α therapy for chronic viral hepatitis
F Dumoulin, L Leifeld, T Sauerbruch, U Spengler |
Biomedecine & Pharmacotherapy | 1999 |
Type I Interferons
ED Maeyer, JD Maeyer-Guignard |
International Reviews of Immunology | 1998 |
Bleomycin-induced lung injury is enhanced by interferon-α
N Berkman, RH Goldstein, R Breuer |
Life Sciences | 1997 |
Phase I Study Combining Tumor Necrosis Factor with Interferon-α and Interleukin-2
ED Eskander, HA Harvey, E Givant, A Lipton |
American Journal of Clinical Oncology | 1997 |
Common cancers—Immunotherapy and multidisciplinary therapy: Parts III and IV
WD Quan, CS Palackdharry |
Disease-a-Month | 1997 |
Weekly 5-Fluorouracil and Interferon-alfa-2b in Metastatic Cancer
WD Quan, R Casal |
Cancer Biotherapy & Radiopharmaceuticals | 1996 |
Beta-Interferon
HJ Obert |
1995 | |
Interferon as adjunctive treatment for non-metastatic renal cell carcinoma
S Takahashi, T Tanigawa, M Imagawa, H Mimata, Y Nomura, J Ogata |
British Journal of Urology | 1994 |
Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin
WC Lambert, B Giannotti, WA van Vloten |
1994 | |
Cancer Treatment An Update
P Banzet, JF Holland, D Khayat, M Weil |
1994 | |
Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue
E Selzer, A Wilfing, V Sexl, M Freissmuth |
Naunyn-Schmiedeberg's Archives of Pharmacology | 1994 |
The role of interleukin-2 in the treatment of cancer patients
J Wagstaff |
1993 | |
Current Research and Clinical Management of Melanoma
L Nathanson |
1993 | |
Modulation of 2′,5′-OHgoadenylate Synthetase in Patients Treated with Alpha-Interferon: Effects of Dose, Schedule, and Route of Administration
JA Merritt, LA Ball, KM Sielaff, DM Meltzer, EC Borden |
Journal of Interferon Research | 1992 |
Interferons: Pleiotropic cellular modulators
EC Borden |
Clinical Immunology and Immunopathology | 1992 |
A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies
S Bernard, P Gill, P Rosen, M Gavigan, A Steagall, E Ellingham, T Morgan, G Janic, H Ozer |
Medical and Pediatric Oncology | 1991 |
Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck
DR Vlock, J Johnson, E Myers, R Day, WE Gooding, T Whiteside, K Pelch, B Sigler, R Wagner, D Colao, D Rust |
Head & Neck | 1991 |
Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro
WR Bezwoda, T Golombick, R Dansey, J Keeping |
European Journal of Cancer and Clinical Oncology | 1991 |
Melanoma Research: Genetics, Growth Factors, Metastases, and Antigens
L Nathanson |
1991 | |
Immunotherapy of Renal Cell Carcinoma
FM Debruyne, RM Bukowski, JE Pontes, PH de Mulder |
1991 | |
The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals
YK Yoo, JB Gavaler, K Chen, TL Whiteside, DH Thiel |
Clinical & Experimental Immunology | 1990 |
Lymphokines and cytokines as cancer treatment.Immunotherapy realized
EC Borden, PM Sondel |
Cancer | 1990 |
Biological and Clinical Effects of Interferon-βserat Two Doses
EC Borden, JJ Rinehart, BE Storer, DL Trump, DM Paulnock, AP Teitelbaum |
Journal of Interferon Research | 1990 |
New therapeutic strategies in the treatment of murine diseases induced by virus and solid tumors: Biology and implications for the potential treatment of human leukemia, AIDS, and solid tumors
RN Shen, L Lu, HE Broxmeyer |
Critical Reviews in Oncology/Hematology | 1990 |
Modulation of lymphoid cell sensitivity to interferon by thyroid hormones
M Provinciali, N Fabris |
Journal of Endocrinological Investigation | 1990 |
Generation of tumoricidal effector cells with a novel potentiator: N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763)
BS Wang, AL Lumanglas, YI Lin, FE Durr |
International Journal of Immunopharmacology | 1990 |
Genital Papillomavirus Infections
G Gross, S Jablonska, H Pfister, HE Stegner |
1990 | |
The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.
Yoo YK, Gavaler JB, Chen K, Whiteside TL, van Thiel DH |
Clinical & Experimental Immunology | 1990 |
Immunological recovery and dose evaluation in IFN-α treatment of hairy cell leukemia: Analysis of leukocyte differentiation antigens, NK and 2‘,5’-oligoadenylate synthetase activity
B Nielsen, M Hokland, J Justesen, H Hasselbalch, J Ellegaard, P Hokland |
European Journal of Haematology | 1989 |
Induced Proteins in Human Peripheral Mononuclear Cells Over a Range of Clinically Tolerable Doses of Interferon-γ
DM Paulnock, KA Havlin, BM Storer, GT Spear, KM Sielaff, EC Borden |
Journal of Interferon Research | 1989 |
The role of interferons in the treatment of malignant neoplasms
JR Murren, AC Buzaid |
The Yale journal of biology and medicine | 1989 |
Immunosuppressive effects of recombinant interferon-α during long-term treatment of cancer patients
JV Teichmann, G Sieber, WD Ludwig, H Ruehl |
Cancer | 1989 |
Low-dose recombinant interferon-α in the treatment of cutaneous T-cell lympbomas
B Dreno, WY Godefroy, M Fleischmann, B Bureau, P Lioutx |
British Journal of Dermatology | 1989 |
in vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma
S Osanto, R Jansen, AM Naipal, JW Gratama, AV Leeuwen, FJ Cleton |
International Journal of Cancer | 1989 |
Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-α-2b treatment
B Nielsen, P Hokland, J Ellegaard, H Hasselbalch, M Hokland |
Leukemia Research | 1989 |
Cancer Metastasis
V Schirrmacher, R Schwartz-Albiez |
1989 | |
Exercise and Natural Killer Cells: What is the Relationship?
LT Mackinnon |
Sports Medicine | 1989 |
IFN-treatment of B16-F1 versus B16-F10: Relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread
M Zöller |
Clinical & Experimental Metastasis | 1988 |
Interferons Affect Oxygen Metabolism in Human Neutrophil Granulocytes
K Lappegård, H Benestad, H Rollag |
Journal of Interferon Research | 1988 |
Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease
PL Black, H Phillips, HR Tribble, R Pennington, M Schneider, JE Talmadge |
Journal of Cellular Biochemistry | 1988 |
Modulation of Immune Functions by Long-Term Treatment with Recombinant Interferon-α2in a Patient with Hairy-Cell Leukemia
J Teichmann, G Sieber, WD Ludwig, H Ruehl |
Journal of Interferon Research | 1988 |
Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses
AJ Pinto, PS Morahan, MA Brinton |
International Journal of Immunopharmacology | 1988 |
Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias
JM Bennett, KA Foon |
1988 | |
Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon
V Carreño, JC Porres, I Mora, J Bartolomé, C Bas, J Gutiez, J Cortés, CH Guio |
Liver | 1987 |
Therapeutic potential of cytokines
JE Talmadge |
Clinical Immunology Newsletter | 1987 |
Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection
I Mora, JC Porres, J Bartolomé, JA Quiroga, J Gutiez, CH Guio, C Bas, V Carreño |
Journal of Hepatology | 1987 |
Anticarcinogenesis and Radiation Protection
PA Cerutti, OF Nygaard, MG Simic |
1987 | |
Separation of Human Natural Killer Cell Subpopulations Differentially Responsive to Interferon Potentiation
BS Edwards, RC Fuhlbrigge, EC Borden |
Journal of Interferon Research | 1986 |
Modulation of 2′,5′-Oligoadenylate Synthetase in Patients Treated with Alpha-Interferon: Effects of Dose, Schedule, and Route of Administration
JA Merritt, LA Ball, KM Sielaff, DM Meltzer, EC Borden |
Journal of Interferon Research | 1986 |
A Biological Approach to Optimize Interferon Treatment in Hairy Cell Leukemia
G Gastl, W Aulitzky, H Tilg, K Nachbaur, J Troppmair, R Flener, C Huber |
Immunobiology | 1986 |
Alpha interferon in the treatment of hematologic malignancies
MS Roth, KA Foon |
The American Journal of Medicine | 1986 |